• Lymphoma patients with ≤2 lines of prior therapy, patients with multiple myeloma with one line of therapy;

• Patients who had achieved at least partial response (PR);

• Patients who were eligible for autologous peripheral blood stem cell transplantation

• Age≥18 and≤65 years;

• Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Patients who have an estimated life expectancy of more than three months

• Fertile patients must be willing to use reliable contraception during the clinical study period and for 90 days after the last dose and have a negative serological pregnancy test within 72 hours prior to the first dose.

• Patients must be able and willing to give written informed consent prior to any study-related procedures